Examining the effect of harmine in regulating the apoptosis pathway through the activation of the antioxidant pathway control of FOXO1 protein expression in wistar male rats with non-alcoholic fatty liver disease
Subject Areas : Journal of Animal BiologyNazanin Lotfizadeh 1 , Hanieh Jafary 2 * , Nasim Hayati Roodbari 3
1 - Department of Biology, SR.C., Islamic Azad University, Tehran, Iran
2 - Department of Biology, SR.C., Islamic Azad University, Tehran, Iran
3 - Department of Biology, SR.C., Islamic Azad University, Tehran, Iran
Keywords: Harmine, fatty liver, apoptosis, antioxidant, FOXO1 protein,
Abstract :
The liver is one of the most important and vital organs in the body, and non-alcoholic fatty liver disease (NAFLD) is one of the most common liver disorders, and the number of people suffering from it is increasing. The aim of this study is to investigate harmine on the serum levels of liver index enzymes, lipid profile and the amount of FOXO1 transcription factor in rats suffering from non-alcoholic fatty liver disease. For this purpose, 18 Wistar male rats were considered and divided into three control groups, model group and model group + Harmin (20 mg/kg). Two model groups and treated with harmine with a special diet were affected with fatty liver and then the third group was gavage with harmine for 4 weeks. Total oxidant (TOS), total antioxidant (TAC), malone dialdehyde (MDA) and hepatic superoxide dismutase (SOD) activity were measured. The activities of alkaline phosphatase (ALP), alanine aminotransferase (SGPT), aspartate aminotransferase (SGOT) enzymes were measured in serum. Lipid profile (LDL, HDL, VLDL, cholesterol, triglyceride), glucose and apoptosis were also measured. The results indicate that apoptosis in the sample model treated with harmine showed a significant decrease compared to the fatty liver model group. The amount of LDL, VLDL, TOS, MDA, triglyceride, cholesterol, glucose and the activity of ALP, SGOT, SGOT, FOXO1 protein and apoptosis in the group treated with harmine showed a significant decrease compared to the fatty liver model group. The level of SOD enzyme activity, TAC and HDL levels in the models treated with harmine showed a significant increase compared to the model group. It seems that harmine can be a good potential for further investigations to introduce a fatty liver controlling factor using the FOXO1 regulatory pathway.
1- Cataldo I., Sarcognato S., Sacchi D., Cacciatore M., Baciorri F., Mangia, A., Cazzagon F., Guido, M. 2021. Pathology of non-alcoholic fatty liver disease. Pathologica, 113(3), 194-202.
2- Cheng J., Yang S., Chou D., Chen J., Li Y., Haung C., Chen H., Zhou Y. 2024. FOXO1 induced fatty acid oxidation in hepatic cells by targeting ALDH1L2. Gastroentrology and Hepatology, 39(10): 2197-2207.
3- Ciardullo S., Muraca E., Vergani M., Invernizzi P., Perseghin G. 2024. Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions. Gastroenterology Report, 12.
4- Efati M., Khorrami M., Zarei Mahmmudabadi A., Raouf Sarshoori J. 2016. Induction of an animal model of non-alcoholic fatty liver disease using a formulated high-fat diet. Journal of Babol University of Medical Sciences, 18(11): 57-62.
5- Ghanbari A., Jalili C., Salahshoor M. R., Javanmardy S., Ravankhah S., Akhshi N. 2022. Harmine mitigates cisplatin-induced renal injury in male mice through antioxidant, anti-inflammatory and anti-apoptosis effects. Research in Pharmaceutical Sciences, 17(4), 417-427.
6- Guan Y., Louis E. D., Zheng W. 2001. Toxicokinetics of tremorogenic natural products, harmane and harmine in male Sprague-Dawley rats. Journal of toxicology and environmental health Part A, 64(8):645-660.
7- Guo S., Mangal R., Dandu C., Geng X., Ding Y. 2022. Role of forkhead box protein O1 (FoxO1) in stroke: A literature review. Aging and Disease, 13(2):521-533.
8- Kim M., Ahn S., Hur N., Oh S., Son C. 2024. The additive effect of herbal medicines on lifestyle modification in the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis. Frontiers, 15.
9- Lv Y., Liang H., Li J., Li X., Tang X., Gao S., Xiao L. 2021. Central inhibition prevents the in vivo acute toxicity of harmine in mice. The Journal of Toxicological Sciences, 46(6):289-301.
10- Morsy M.H.E., Nabil Z.I., Darwish S.T., A-Eisa R.A., Mehana A.E. 2023. Anti-Diabetic and Anti-Adipogenic Effect of Harmine in High-Fat-Diet-Induced Diabetes in Mice. Life, 13(8):1693.
11- Ogawa W. 2023. Insulin resistance and adipose tissue. Diabetology international, 14(2):117-118. 12- Paternostro R., Trauner M. 2022. Current treatment of non‐alcoholic fatty liver disease. Journal of internal medicine, 292(2):190-204.
13- Peng S., Li W., Hou N., Huang N. 2020. A Review of FoxO1-Regulated Metabolic Diseases and Related Drug Discoveries. Cells, 9(1):184.
14- Rong L., Zou J., Ran W., Qi X., Chen Y., Cui H., Guo J. 2023. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Frontiers, 13.
15- Rostamizadeh P., Mazloom Z. 2019. The Effect of Licorice and Probiotics on Nonalcoholic Fatty Liver Disease (NAFLD): A Systematic Review. International Journal of Nutrition Sciences, 4(4):163-169.
16- Salahshoor M.R., Roshanak Shiva., Motavalian V., Jalili C. 2019. Effect of Harmine on Nicotine‑Induced Kidney Dysfunction in Male Mice. International journal of preventive medicine, 10(1): 97.
17- Sha X., Zou X., Liu S., Guan C., Shi W., Gao J., Zhong X., Jiang X. 2024. Forkhead box O1 in metabolic dysfunction-associated fatty liver disease: molecular mechanisms and drug research. Frontiers in nutrition, 11: 1426780.
18- Xu D., Qu X., Yang T., Sheng M., Bian X., Zhan Y., Tian Y., Lin Y., Wang X., Ke M., Jiang L., Li C., Xia Q., Farmer D., Ke B. 2024. The Foxo1-YAP-Notch1 axis reprograms STING-mediated innate immunity in NASH progression. Experimental & Molecular Medicine, 56:1843-1855.
19- Zachou M., Flevari P., Nasiri-Ansari N., Varytimiadis C., Kalaitzakis E., Kassi E., Androutsakos T. 2023. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review. European Journal of Clinical Pharmacology, 80:127-150.
20- Zhang L., Dengchang L. 2020. Pharmacological effects of harmine and its derivatives: a review. Archives of pharmacal research, 43(12):1259-1275.
21- Zhang X., Jiang L., Liu H. 2021. Forkhead Box Protein O1: Functional Diversity and Post-Translational Modification, a New Therapeutic Target?. Drug design, development and therapy, 15:1851-1860.